ArticleBMC cancer2025
CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Aging disrupts spatiotemporal coordination in the cycling murine ovary.Nature aging · 2026Article
- CMSS1 promoted CXCL8-CXCR1/2 pathway to accelerate the invasion and immune escape of triple-negative breast cancer.Journal of molecular histology · 2026Article
- RNA-binding protein gene NOP58 exhibits crucial prognostic and therapeutic value in Ewing sarcoma.Hereditas · 2025Article
- Cms1 Ribosomal Small Subunit Homolog Promotes HCC Proliferation and Migration by Modulating the TNF/NF-κB Signaling Pathway.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Cms1 ribosomal small subunit homolog (CMSS1), an RNA-binding protein (RBP), plays a crucial role in tumor development. However, the prognostic and immunological role of CMSS1 in non-small cell lung cancer (NSCLC) remains unclear.
methodsDifferentially expressed RBP genes were identified using The Cancer Genome Atlas (TCGA) database, and the hub RBP-related gene, CMSS1, was selected through univariate Cox regression analysis and Kaplan-Meier tests. To evaluate the prognostic capacity of the CMSS1, time-dependent receiver operating characteristic curves, Kaplan-Meier curves and multivariate Cox regression analyses were conducted. The relationship between the CMSS1 gene and tumor-infiltrating immune cells was assessed using the ImmuCellAI algorithm. Additionally, a loss-of-function assay was performed to investigate the functional role of CMSS1 in NSCLC cells.
resultsBioinformatic analysis revealed that CMSS1, an RBP-related gene, was notably upregulated in NSCLC tumors, with elevated RNA levels correlating with poor prognosis in NSCLC patients. Immune cell infiltration analysis showed that CMSS1 expression was negatively correlated with CD4 T cells and was positively correlated with macrophages and Tregs. Furthermore, RT-qPCR and western blot confirmed the increased CMSS1 mRNA and CMSS1 protein levels in NSCLC cell lines. Significantly, downregulation of CMSS1 inhibited NSCLC cell viability, migration and invasion.
conclusionOur findings suggest that CMSS1 may serve as both a prognostic indicator and a therapeutic target for patients with NSCLC. This study may provide potential guidance for precision therapy and accurate prognosis prediction for patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.